Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas

被引:34
作者
Takekoshi, K
Isobe, K
Yashiro, T
Hara, H
Ishii, K
Kawakami, Y
Nakai, T
Okuda, Y
机构
[1] Univ Tsukuba, Inst Clin Med, Dept Clin Pathol, Tsukuba, Ibaraki 3058575, Japan
[2] Univ Tsukuba, Inst Clin Med, Dept Surg, Tsukuba, Ibaraki 3058575, Japan
[3] Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan
关键词
angiogenesis; vascular endothelial growth factor (VEGF); pheochromocytomas;
D O I
10.1016/J.lfs.2003.07.036
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pheochromocytomas are well-vascularized tumors, suggesting that a potent angiogenic factor may be involved in the mechanism of their formation. As vascular endothelial growth factor (VEGF) is a potent mitogen for vascular endothelial cells, here we have investigated the mRNA and protein expression of VEGF and the mRNA expression of its two receptors (Flt-1 and Flk-1/KDR) in pheochromocytomas tissue. An increase in VEGF mRNA (mainly isoforms VEGF(121) and VEGF(165)) and in VEGF protein expression were observed by semi-quantitative RT-PCR and Western blot, respectively, compared to normal adrenomedullary tissue. Flk-1/KDR, and Flt-1 levels of mRNA were also increased markedly in tumors and correlated with levels of VEGF mRNA. Therefore, we speculate that upregulation of VEGF expression and its receptors might be important in the pathogenesis of pheochromocytomas. (C) 2003 Published by Elsevier Inc.
引用
收藏
页码:863 / 871
页数:9
相关论文
共 38 条
[1]   EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ITS RECEPTORS FLT AND KDR IN OVARIAN-CARCINOMA [J].
BOOCOCK, CA ;
CHARNOCKJONES, DS ;
SHARKEY, AM ;
MCLAREN, J ;
BARKER, PJ ;
WRIGHT, KA ;
TWENTYMAN, PR ;
SMITH, SK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (07) :506-516
[2]   Investigation of phaeochromocytoma [J].
Bouloux, PMG ;
Fakeeh, M .
CLINICAL ENDOCRINOLOGY, 1995, 43 (06) :657-664
[3]  
BROWN LF, 1993, CANCER RES, V53, P4727
[4]   Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein [J].
Cockman, ME ;
Masson, N ;
Mole, DR ;
Jaakkola, P ;
Chang, GW ;
Clifford, SC ;
Maher, ER ;
Pugh, CW ;
Ratcliffe, PJ ;
Maxwell, PH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (33) :25733-25741
[5]  
de Krijger RR, 1999, J PATHOL, V188, P51
[6]   THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR [J].
DEVRIES, C ;
ESCOBEDO, JA ;
UENO, H ;
HOUCK, K ;
FERRARA, N ;
WILLIAMS, LT .
SCIENCE, 1992, 255 (5047) :989-991
[7]   MUTATIONS IN THE RET PROTOONCOGENE ARE ASSOCIATED WITH MEN 2A AND FMTC [J].
DONISKELLER, H ;
DOU, SS ;
CHI, D ;
CARLSON, KM ;
TOSHIMA, K ;
LAIRMORE, TC ;
HOWE, JR ;
MOLEY, JF ;
GOODFELLOW, P ;
WELLS, SA .
HUMAN MOLECULAR GENETICS, 1993, 2 (07) :851-856
[9]   MUTATIONS IN THE RET PROTOONCOGENE AND THE VON HIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE IN SPORADIC AND SYNDROMIC PHEOCHROMOCYTOMAS [J].
ENG, C ;
CROSSEY, PA ;
MULLIGAN, LM ;
HEALEY, CS ;
HOUGHTON, C ;
PROWSE, A ;
CHEW, SL ;
DAHIA, PLM ;
ORIORDAN, JLH ;
TOLEDO, SPA ;
SMITH, DP ;
MAHER, ER ;
PONDER, BAJ .
JOURNAL OF MEDICAL GENETICS, 1995, 32 (12) :934-937
[10]   Angiogenesis and vascular architecture in pheochromocytomas - Distinctive traits in malignant tumors [J].
Favier, J ;
Plouin, PF ;
Corvol, P ;
Gasc, JM .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (04) :1235-1246